The NHLBI LAM Registry: Prognostic physiological and radiological biomarkers emerge from a 15-year prospective longitudinal analysis.
Gupta N , Lee HS , Ryu JH , Taveira-DaSilva AM , Beck GJ , Lee JC , McCarthy K , Finlay GA , Brown KK , Ruoss SJ , Avila NA , Moss J , McCormack FX , 
Chest.2018 Jun 22 ; ():.
PubMedで表示
Google翻訳で開く
(8view , 0users)
Full Text Sources
The natural history of lymphangioleiomyomatosis is mainly derived from retrospective cohort analyses and remains incompletely understood. A National Institutes of Health LAM Registry was established to define the natural history and identify prognostic biomarkers that can help guide management and decision-making in patients with LAM.
PMID: 29940164 [PubMed - as supplied by publisher]
PMID: 29940164 [PubMed - as supplied by publisher]
関連論文
- [Review] Clinical and molecular insights into lymphangioleiomyomatosis.
- Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry.
- Clinical Predictors of Mortality and Cause of Death in Lymphangioleiomyomatosis: A Population-based Registry.
- Severity and outcome of cystic lung disease in women with tuberous sclerosis complex.
- A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.